Nurix drops after new early-stage trial data for lead asset

June 13, 2025 04:46 AM AEST | By EODHD

Google News:

Nurix drops after new early-stage trial data for lead asset — Image source: Kalkine Media

Recent News

Happy Father's Day - Training Sons to become responsible fathers

Wood Panel Wall USA Introduces Acoustic Slat Panels to Enhance Sound Q...

World Digital Introduces Innovative E‑Commerce Strategies Amid Global...

Alex Miller Keeps Classic Country Flame Burning With Alan Jackson Song...

[A cancer cell is being targeted by immune cells: T cells, NK cells, macrophages. Cellular interaction, phagocytosis process, activation of a mast cell, histamine granules] quantic69/iStock via Getty Images Shares of Nurix Therapeutics (NASDAQ:NRIX [https://seekingalpha.com/symbol/NRIX]) fell on Thursday after the company updated data from a Phase 1a/b clinical trial for its lead asset bexobrutideg (NX-5948) in patients with relapsed or refractory B-cell malignancies. The data had been selected for a presentation at the ongoing European Hematology Association Congress. According to Nurix (NASDAQ:NRIX [https://seekingalpha.com/symbol/NRIX]), its Bruton’s tyrosine kinase degrader achieved an overall objective response rate of 80.9% among 47 patients with relapsed or refractory chronic lymphocytic leukemia. Citing data from 19 patients, the company added that those with Waldenström Macroglobulinemia witnessed an overall objective response rate of 84.2%.

The analysis was based on a data cut on March 12 when the median follow-up period had approached nine months. The study, designed to test oral bexobrutide doses ranging from 50 mg to 600 mg, indicated a well-tolerated safety profile for the drug with no safety signals, the company noted. Nurix (NASDAQ:NRIX [https://seekingalpha.com/symbol/NRIX]) reaffirmed its plans to begin pivotal trials for bexobrutideg this year. [https://seekingalpha.com/pr/20134575-nurix-therapeutics-presents-updated-positive-data-demonstrating-durable-deepening-responses] MORE ON NURIX * Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential [https://seekingalpha.com/article/4776031-nurix-therapeutics-irak4-gs-6971-isnt-only-protein-degrader-with-big-potential] * Nurix Therapeutics: A Story To Monitor [https://seekingalpha.com/article/4759282-nurix-therapeutics-a-story-to-monitor] * Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation [https://seekingalpha.com/article/4748505-nurix-therapeutics-speculative-bet-on-btk-degraders-and-targeted-protein-modulation] * Nurix gets FDA clearance to initiate trial for its anti-inflammatory drug candidate [https://seekingalpha.com/news/4432156-nurix-gets-fda-clearance-to-initiate-trial-for-its-anti-inflammatory-drug-candidate] * Nurix Therapeutics GAAP EPS of -$0.67 beats by $0.11, revenue of $18.45M beats by $5.42M [https://seekingalpha.com/news/4429579-nurix-therapeutics-gaap-eps-of-0_67-beats-by-0_11-revenue-of-18_45m-beats-by-5_42m]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.